1
ALL1
Indication BioScienceYear
1
ALL1
2021DEALS // DEV.
1
ALL1
DevelopmentsCountry
1
ALL1
U.S.A1
ALL1
InapplicableTherapeutic Area
1
ALL1
Cardiology/Vascular DiseasesStudy Phase
1
ALL1
PreclinicalDeal Type
1
ALL1
InapplicableProduct Type
1
ALL1
Other Small MoleculeDosage Form
1
ALL1
UndisclosedLead Product
1
ALL1
AtorvastatinTarget
1
ALL1
HMG-CoA reductaseLead Product(s) : Atorvastatin,Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Indication Bioscience Granted First Patent for Statin Plus Cannabidiol (CBD) Combination
Details : The U.S. Patent covers pharmaceutical compositions comprising a statin and a cannabinoid, and their use for the treatment of hypercholesterolemia and atherosclerosis.
Product Name : Atrova+
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 02, 2021
Lead Product(s) : Atorvastatin,Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable